Physician profile
Roger Holman
NPI 1073518270
$14,280.43
in general payments reported to CMS, 2019-2025
58 companies · $1,612 in 2025
The $1,612 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,306 · 2020: $1,558 · 2021: $2,393 · 2022: $2,427 · 2023: $2,574 · 2024: $2,412 · 2025: $1,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,502 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,501.68 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,104.98 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,527.21 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,238.94 | 2019-2024 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Pfizer INC. | $1,217.06 | 2019-2025 | |
| Lilly USA, LLC | $1,195.01 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $834.17 | 2019-2025 | Ozempic, Saxenda, Wegovy |
| Glaxosmithkline, LLC. | $726.99 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $518.70 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $462.06 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $427.77 | 2019-2024 | Qelbree, Qelbree |
| Amgen INC. | $420.03 | 2019-2025 | Repatha, Otezla, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $395.25 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $317.65 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $311.75 | 2019-2025 | Eliquis, Camzyos |
| Exact Sciences Corporation | $213.15 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Holman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.